Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

Bullboard (GREY:IPHAF)

View:
Post by gmcsleon Feb 03, 2010 4:15pm

More Volume

Is needed........I think it's comming real soon!
Post by ISAloser247on Feb 03, 2010 10:51am

Re: investandpray

   Just some advice from the FPX board by investandprey, "Patience rewards those willing"
Post by blogon Jan 31, 2010 6:02pm

Making money

It’s possible these smart guys and gals will figure out away to make money for shareholders. https://www.isotechnika.com/governance/board_of_directors/berger/
Comment by professional11on Jan 31, 2010 12:11am

RE: cure for RA?

This type of therapy requires the co-development of a targeted delivery vehicle - and is at least 10 years away from the market.  And if/when it reaches the market, it will cover only a small ...more  
Post by teeveeon Jan 30, 2010 1:17am

cure for RA?

this news is very interesting. If this works in humans, one can only wonder how many other immune system related diseases can be cured or controlled without drugs like voclosporin or other immune ...more  
Post by professional11on Jan 29, 2010 4:02pm

From the BioWorld survey of CEOs

Just read this today... thought some of you may be interested.- 203 biotech CEOs surveyed- Top-paid is Kevin Sharer, CEO of Amgen- Median salary for the surveyed CEOs increased to $445,466 ...more  
Post by blogon Jan 29, 2010 11:38am

Maybe

 Maybe in February we will get some info.
Post by antoninuson Jan 28, 2010 10:33am

a funny thing happened on the way to...

on the way to psoriasis and transplant, a funny thing happened...they were caught short of money to be adequately prepared in case roche pulled the plug, which of course they did...and so rather ...more  
Post by ISAloser247on Jan 27, 2010 4:43pm

Mea Culpa II

          I had to check the First Point Minerals board.  It would seem that We were forged at the same Kettle Foundry.
Post by ISAloser247on Jan 27, 2010 4:03pm

Re: Mera Culpa

    You are right !
Comment by Investandprayon Jan 27, 2010 11:59am

RE: Re:Just another PUMP/DUMPER

   Your name says it all pal "LOSER". I have been a shareholder of ISA for 7 years. My first purchase was when the stock was $5 a share back in the good old days. I have been ...more  
Post by ISAloser247on Jan 27, 2010 11:14am

Re:Just another PUMP/DUMPER

  From Investandpray's January 24,2010 post,"India is a huge market , growing middle class" , "investors in the U.S. will buy ISA because of LUX",  " Thank God ...more  
Comment by Investandprayon Jan 27, 2010 10:31am

RE: sold it all for now

      Your sell strategy today is for sure a safe way to play it. Your note about the short cash position is a concern however the company did say at the AGM in 09 that ...more  
Comment by macbethorfauston Jan 26, 2010 8:49pm

RE: roche

”but still a few years away from approval”?? Do you mean psoriasis (US) and transplant?  Uvietis is targeted for approval by the summer (so say the fall)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities